The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara (Ustekinumab), marking a significant milestone for ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab) has been added to the Costco Member ...

JERSEY CITY, N.J., March 12, 2025 /PRNewswire/ -- Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following ...

Stelara (ustekinumab, Janssen) is an interleukin (IL)-12 and IL-23 inhibitor approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, and Formycon AG, a leading, independent developer of high-quality biosimilars, announced today that the ustekinumab biosimilar ...

The FDA has provisionally determined that SELARSDI will be interchangeable with the reference biologic Stelara ®, following the expiration of exclusivity for the first interchangeable biosimilar ...

Both etanercept and ustekinumab have been shown to be strikingly effective in patients with psoriasis. A phase III trial comparing these two biologic agents for the treatment of moderate-to-severe ...

Later this month, the US Food and Drug Administration (FDA) will decide whether a new psoriasis drug, Stelara (ustekinumab), can enter the market. The human monoclonal antibody (mAb), developed by ...

granting marketing authorization for YESINTEK®, a biosimilar of Ustekinumab. This approval positions Biocon Biologics for deeper penetration into the European biosimilars market, strengthening ...

STEQEYMA ®, one of the first-wave biosimilars to STELARA ®, is now available in the U.S. Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale ...